The Immune, Inflammatory and Hematological Response in COVID-19 Patients, According to the Severity of the Disease
暂无分享,去创建一个
L. Iancu | O. Dorneanu | A. Vâță | M. Vlad | Felicia Trofin | C. Luncă | E. Buzilă | E. Nastase
[1] D. Talwar,et al. Association of serum ferritin with COVID-19 in a cross-sectional study of 200 intensive care unit patients in a rural hospital: Is ferritin the forgotten biomarker of mortality in severe COVID-19? , 2022, Journal of family medicine and primary care.
[2] D. Talwar,et al. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital:A Cross-sectional Study , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.
[3] Y. Shoenfeld,et al. Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form , 2021, Pathogens.
[4] Yongxiang Yi,et al. Neutrophils and Lymphocytes Can Help Distinguish Asymptomatic COVID-19 From Moderate COVID-19 , 2021, Frontiers in Cellular and Infection Microbiology.
[5] Philip R. O. Payne,et al. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19 , 2021, Research square.
[6] Weijia Xie,et al. Early kidney injury predicts disease progression in patients with COVID-19: a cohort study , 2021, BMC Infectious Diseases.
[7] C. Bondor,et al. Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients , 2021, PloS one.
[8] H. Bøtker,et al. COVID-19 related cardiac complications - from clinical evidences to basic mechanisms. Opinion paper of the ESC Working Group on Cellular Biology of the Heart. , 2021, Cardiovascular research.
[9] F. J. Carod-Artal,et al. [Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved]. , 2021, Revista de neurologia.
[10] H. Yassine,et al. Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality , 2021, Frontiers in Immunology.
[11] K. Bhaskaran,et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform , 2021, The Lancet.
[12] L. Anastácio,et al. Risk factors for critical illness and death among adult Brazilians with COVID-19 , 2021, Revista da Sociedade Brasileira de Medicina Tropical.
[13] M. Ouimet,et al. Editorial: Covid-19 Mechanisms on Cardio-Vascular Dysfunction: From Membrane Receptors to Immune Response , 2021, Frontiers in Cardiovascular Medicine.
[14] R. Müller,et al. Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease , 2021, Infection.
[15] K. Khunti,et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England , 2021, The Lancet Diabetes & Endocrinology.
[16] D. Freedman,et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020 , 2021, MMWR. Morbidity and mortality weekly report.
[17] A. Spottke,et al. Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort , 2021, Movement disorders : official journal of the Movement Disorder Society.
[18] A. Gasbarrini,et al. Predictors of in-hospital mortality AND death RISK STRATIFICATION among COVID-19 PATIENTS aged ≥ 80 YEARs OLD , 2021, Archives of Gerontology and Geriatrics.
[19] K. Telle,et al. Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study , 2021, Scandinavian journal of public health.
[20] W. Lu,et al. Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19 , 2021, International journal of medical sciences.
[21] Ling Zheng,et al. Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study , 2020, BMC Infectious Diseases.
[22] E. Devriendt,et al. Risk factors for severe COVID-19 disease and death in patients aged 70 and over: a retrospective observational cohort study , 2020, Acta clinica Belgica.
[23] J. Hodosy,et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak , 2020, BMC Infectious Diseases.
[24] S. Hannawi,et al. D-dimer, Troponin, and Urea Level at Presentation With COVID-19 can Predict ICU Admission: A Single Centered Study , 2020, Frontiers in Medicine.
[25] Pei Wang. Significance of IgA antibody testing for early detection of SARS‐CoV‐2 , 2020, Journal of medical virology.
[26] T. Greenhalgh,et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services , 2020, BMC Health Services Research.
[27] H. Peckham,et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission , 2020, Nature Communications.
[28] B. O. Manin,et al. A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level , 2020, Frontiers in Public Health.
[29] U. Merle,et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry , 2020, Annals of Hematology.
[30] L. Grohskopf,et al. Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons , 2020, Clinical Infectious Diseases.
[31] H. J. Kim,et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19 , 2020, European Respiratory Journal.
[32] E. Miller,et al. Risk factors for severe acute respiratory syndrome coronavirus 2 infection in pregnant women , 2020, American Journal of Obstetrics & Gynecology Mfm.
[33] S. Pancani,et al. Closing the serological gap in the diagnostic testing for COVID‐19: The value of anti‐SARS‐CoV‐2 IgA antibodies , 2020, Journal of medical virology.
[34] Sheng Hu,et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study , 2020, Journal of Translational Medicine.
[35] M. Antonelli,et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. , 2020, JAMA internal medicine.
[36] A. Sanyaolu,et al. Comorbidity and its Impact on Patients with COVID-19 , 2020, SN Comprehensive Clinical Medicine.
[37] Xi Zhou,et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients , 2020, Signal Transduction and Targeted Therapy.
[38] Yajuan Li,et al. Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.
[39] B. Lipworth,et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[40] H. Hakonarson,et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.
[41] H. Hou,et al. Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19 , 2020, Clinical and experimental immunology.
[42] E. Theel,et al. The Role of Antibody Testing for SARS-CoV-2: Is There One? , 2020, Journal of Clinical Microbiology.
[43] Florian Thiery,et al. Linked COVID-19 Data: Johns Hopkins University (JHU) and European Centre for Disease Prevention and Control (ECDC) , 2020 .
[44] T. Velavan,et al. Mild versus severe COVID-19: Laboratory markers , 2020, International Journal of Infectious Diseases.
[45] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] Xiuyong Li,et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19 , 2020, Journal of medical virology.
[47] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[48] Tian Huang,et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.
[49] R. Lu,et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.
[50] Li Zhang,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[51] L Rampal,et al. Coronavirus disease (COVID-19) pandemic. , 2020, The Medical journal of Malaysia.
[52] C. Akdis,et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.
[53] L. Chen,et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[54] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[55] Xiao-Neng Mo,et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients , 2020, Emerging microbes & infections.